← Issue №19/ week of Nov 8, 2026/Hepatology

Global, regional, and national burden of gallbladder and biliary diseases in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

From GI Signals issue №19: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology systematic review · Nov 4, 2026 · Lancet GH · IF 39.1

Global, regional, and national burden of gallbladder and biliary diseases in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

Epidemiologyepidemiologysystematic reviewhealth services
Clinical takeawayNo clinical action yet: this is an epidemiological study quantifying global burden and trends, not a clinical intervention or guideline.
What it foundGlobal prevalence of gallbladder and biliary diseases increased from 157.4 million (95% UI 134.0 to 183.3) in 1990 to 264.4 million (226.0 to 309.9) in 2023, but age-standardised rates declined from 3573.2 to 2990.1 per 100,000 population.
ContextThis literature reports a systematic analysis of the global burden of gallbladder and biliary diseases, highlighting their significant contribution to digestive disease burden across geographies, sexes, and ages.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

GBD 2023 Gallbladder and Biliary Disease Collaborators · Lancet Gastroenterology & Hepatology · IF 39.1 · PubMed ↗Permalink
← Read the whole of issue №19 Every paper GI Signals surfaces gets a page like this one. All issues